Tags : Antibody Therapies

Biotech COVID-19

Lilly and Junshi Collaborate to Co-Develop Antibody Therapies for the

Shots: Lilly will get an exclusive license to perform clinical development, manufacturing and distribution of products outside of China while Junshi will maintain all rights in Greater China The collaboration will accelerate the clinical development of Junshi’s Ab therapies against COVID-19 globally. Both the companies have submitted the IND application and anticipate the initiation of […]Read More

Biotech COVID-19

AbCellera and Eli Lilly Collaborate to Co-develop Antibody Therapies Targeting

Shots: The alliance will leverage AbCellera’s rapid pandemic response platform, developed under the DARPA P3 program with Eli Lilly’s development & manufacturing capabilities. The companies will equally share the initial development cost while Lilly will be solely responsible for further development, manufacturing & distribution activities The companies have identified ~500+ unique Ab isolated from one […]Read More


Regeneron Expands its Existing Collaboration with HHS’BARDA to Develop Antibody

Shots: The collaboration leverages Regeneron’s VelociSuite technologies including the VelocImmune platform to develop mAb as monothx. or in combination to treat coronavirus (2019-nCoV) In 2017, HHS and Regeneron collaborated for discovery, research, development and manufacturing of an Abs targeting up to 10 pathogens including influenza virus and 2019-nCoV Regeneron’s VelociSuite technologies including the VelocImmune platform […]Read More